In line with conflicting findings regarding the requirement of ERK5 in cell proliferation, several potential mechanisms can explain the distinct phenotypic outcome produced by ERK5 inhibition on RB phosphorylation in ER−/PR−/HER2+ breast cancer cells. Here, RB1 is linked to breast cancer.